By playing, you agree to uListen's Terms and Privacy Policy and YouTube's Terms of Service.
Peter Attia MD#117 – Stanley Perlman, M.D., Ph.D.: Insights from a coronavirus expert on COVID-19
Summaries, chapters, transcripts, and FAQs on this page are made by uListen, not YouTube.
At a glance
WHAT IT’S REALLY ABOUT
Coronavirus Expert Perlman Explains SARS, MERS, COVID-19, Immunity and Preparedness
- Perlman traces his path from PhD training to medical school and pediatric infectious disease, where he studied coronaviruses in mice as a model for demyelinating disease similar to multiple sclerosis.
- He explains how SARS and MERS emerged from animal reservoirs and why both were contained: they spread mainly from people who were already severely ill, and SARS had no ongoing reservoir.
- He argues SARS-CoV-2 combines common-cold-like upper airway transmissibility with SARS/MERS-like lung disease, so a huge denominator of mild cases still produces many deaths.
- He and Attia discuss immunity to common cold coronaviruses, which wanes within a year or two, and the open question of whether a vaccine or prior infection can prevent shedding, not just severe pneumonia.
- They cover therapeutic strategy and preparedness, including antivirals early, immune modulators later, biomarkers to stage disease, and low-regret stockpiles and testing infrastructure.
IDEAS WORTH REMEMBERING
5 ideasSARS and MERS were containable because of how they spread
Perlman says SARS was not contagious until patients were sick, so identification and quarantine worked, and it had no reservoir; MERS has a low human-to-human R0 outside hospitals.
SARS-CoV-2 blends two behaviors
Perlman describes it as a mix of a common cold coronavirus in the upper airway, giving transmissibility, and SARS/MERS-like lung disease, giving severity.
A huge denominator can offset a modest fatality rate
Perlman notes that infecting everybody and killing a few percent, as with the 1918 flu, kills a great many people, and he reasons that if only about one in five infections cause pneumonia, mortality among those with lung disease may resemble SARS or MERS.
Immunity to mild coronavirus infections tends to wane
Perlman says antibodies to common cold coronaviruses fade over a year or two and reinfection occurs, and he expects similar waning after mild COVID-19.
The key vaccine question is preventing transmission
Perlman says protecting an individual from severe pneumonia may be achievable, but how much immunity is needed to prevent shedding is unknown and matters more to society.
WORDS WORTH SAVING
5 quotesCoronaviruses have the unusual characteristic of being huge So the genetic information of a coronavirus is about four times that of the poliovirus, and yet the virus doesn't seem to do that much more than poliovirus.
— Stanley Perlman
But if you infect everybody and you kill 3% or 4%, you're killing a lot of people. So that's what this virus is doing also, because it's transmissible. So readily because it behaves like a common cold coronavirus.
— Stanley Perlman
how do you prepare for a pandemic that you don't have? Because it's something I've been asked about and thought about.
— Stanley Perlman
The other issue, which is equally important, is how much immunity do you need to prevent shedding, to prevent transmissibility to other people? And that's the one that I think is really unknown and to me is more important. Not important to the individual, but to society.
— Stanley Perlman
It's called a hedge. This is what sophisticated companies do. Sophisticated companies hedge their bets, and if the answer is every time a really scary virus emerges in China, we have to spend $3 billion to be ready for it to land here, but guess what? We don't have to shut our economy down as a result.
— Peter Attia
High quality AI-generated summary created from speaker-labeled transcript.
